Tampilkan postingan dengan label EpiPen. Tampilkan semua postingan
Tampilkan postingan dengan label EpiPen. Tampilkan semua postingan

Rabu, 29 Maret 2017

New EpiPen alternative for $4500!


Today’s Managing Health Care Costs Number is $4500



It seems like eons ago that we were arguing over EpiPen – an autoinjector that delivers a dirt-cheap generic medication that can save the life of someone who has an allergic reaction.  The drug was purchased by Mylan pharmaceuticals which progressively raised its price from $100 to $750 – and faced massive public outcry. 

Mylan’s CEO (the daughter of WV Senator Joe Manchin (D)) was subjected to Congressional hearings, and the company lowered the price (from $750 to $600) and introduced a generic version for half the price (which undersold another generic)

One interesting sidenote was that there had been an EpiPen competitor, Auvi-Q, produced by Sanofi, which gave audio instructions for injection. This had been priced competitivelywith EpiPen when it was introduced in 2013 (each was a bit shy of $250 for two doses) - but had been removed from the market due to production issues.

Good news.  Auvi-Q is back!

Not so good news.  Auvi-Q is priced at $4500 for two doses.

WHAT? 

It’s getting hard to summon outrage about pharmaceutical prices (and a lot else).  Why should a delivery system that was priced at $250 in 2013 be marketed for $4500 in 2017?  Obviously, when it comes to pricing there is no shame – the company selling this also sells Evzio, an autoinjector for naloxone  to reverse narcotic overdose for $4500

EpiPen Google searches 


Jumat, 02 September 2016

Because they can!


Today’s Managing Health Care Costs Number is $5.4 million

 Mylan Share Price 



Gretchen Morgenstern’s weekend “Fair Game” column is posted on the NYT website today – it reviews the implications of Mylan’s price increases for EpiPen on executive compensation.

Mylan put in place a special stock grant in 2014 which will be worth over $13 million to its CEO if the company meets its earnings and stock price goals – and could be worth far more. EpiPen’s price increases have been critical to achieving higher earnings and share price.

A company spokesman denied that EpiPen could have a big impact on the stock grant:

Mylan has a large and diverse business, with more than 2,700 products sold in 165 countries and 600 products sold in the U.S. alone. The targets set forth in the one-time special program were not and are not practically achievable based on pricing of any single product.

Not true.  EpiPen represents $1 billion in revenue (of total $9.5 in revenue).   Given that epinephrine costs only a few pennies and all the technology in the injectors is from the 1980s – virtually all EpiPen sales represent gross margin.  The drug needs little marketing – so margin contribution for each unit sold is the vast majority of sales revenue.  Mylan’s net income was $1.46b (2015), $1.34B (2014), and 1.16B(2013) – so EpiPen profits made up a healthy portion of this. 

It’s interesting to note that Mylan’s share priceand EpiPen price increases track very closely.  (Mylan is down about 9% in the last month – which does not show up well on the graph above).
Source

US pharmaceutical companies raise prices because they can -and raising prices absent competition is the best way to raise income, share price, and executive compensation.   Barring government price setting, common in the developed world but anathema here, we will need more competition -and government action to spur such competition.